The FDA has recently approved Spravato, a nasal spray designed to treat major depressive disorder (MDD) in adults who have not responded to at least two oral antidepressants. MDD is one of the most commonly diagnosed mental disorders globally, affecting hundreds of millions of people. Traditional antidepressants often take weeks to show results, and many patients do not achieve remission with a single medication. Studies indicate that only about 30% of individuals experience full symptom relief with one antidepressant, while 50% show no response at all.
The American Gastroenterology Association (AGA) has provided updated guidelines for managing hepatitis B virus reactivation (HBVr) in at-risk individuals. The guidelines focus on preventive strategies and monitoring approaches based on patient risk levels.
The American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) has developed comprehensive guidelines for preventing and managing infections in regional anesthesia and pain management procedures. These guidelines, commissioned in 2020, address a critical need in the field, as approximately 50% of surgical site infections are preventable when proper infection control practices are followed.
A recent study examined the effects of combining the diabetes medication dapagliflozin with a calorie-restricted diet on achieving remission of type 2 diabetes. Conducted at 16 centers in China, the randomized, double-blind, placebo-controlled trial involved 328 patients with type 2 diabetes, aged 20-70, who were either overweight or obese. Participants received either dapagliflozin (10 mg/day) or a placebo with a 500-750 kcal/day diet.
Inventiva, a clinical-stage biopharmaceutical company, has announced promising results from the LEGEND trial, which evaluated the combination of lanifibranor and empagliflozin for treating metabolic dysfunction-associated steatohepatitis (MASH) in patients with type-2 diabetes (T2D). These findings will be presented during an oral plenary session at the upcoming EASL Steatotic Liver Disease (SLD) Summit 2025 in Portugal.
